Stromal Response to Prostate Cancer: Nanotechnology-Based Detection of Thioredoxin-Interacting Protein Partners Distinguishes Prostate Cancer Associated Stroma from That of Benign Prostatic Hyperplasia

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Singer, Elizabeth ^a   Linehan, Jennifer ^a   Babilonia, Gail ^a   Imam, S Ashraf ^b   Smith, David ^a   Loera, Sofia ^a   Wilson, Timothy ^a   Smith, Steven ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; PEROXIREDOXIN 1; THIOREDOXIN INTERACTING PROTEIN; THIOREDOXIN REDUCTASE 1; THIOREDOXIN REDUCTASE 2; PEROXIREDOXIN; PRDX1 PROTEIN, HUMAN; PROTEIN BINDING; TUMOR MARKER; TXNRD1 PROTEIN, HUMAN; TXNRD2 PROTEIN, HUMAN;

AGED; ARTICLE; CLINICAL ARTICLE; FLUORESCENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NANODEVICE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN BINDING; SIGNAL DETECTION; STAINING; STROMA; CD4+ T LYMPHOCYTE; CRYOPRESERVATION; GENETICS; MACROPHAGE; METABOLISM; MIDDLE AGED; NANOTECHNOLOGY; NEUTROPHIL; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; STROMA CELL;

AGED; BIOMARKERS, TUMOR; CD4-POSITIVE T-LYMPHOCYTES; CRYOPRESERVATION; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; NANOTECHNOLOGY; NEUTROPHILS; PEROXIREDOXINS; PROSTATE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN BINDING; STAINING AND LABELING; STROMAL CELLS; THIOREDOXIN REDUCTASE 1; THIOREDOXIN REDUCTASE 2;

EID: 84878790676     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060562     Document Type: Article

References (19)

1. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, et al. (2009) Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214: 761-777.
2. Kramer G, Mitteregger D, Marberger M, (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51: 1202-1216.
3. Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, et al. (2011) Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol 173: 1419-1428.
4. Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG, (2011) Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol 60: 691-698.
5. Klimp AH, Hollema H, Kempinga C, van der Zee AG, de Vries EG, et al. (2001) Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 61: 7305-7309.
6. Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, et al. (1999) Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med 189: 1783-1789.
7. Stanley BA, Sivakumaran V, Shi S, McDonald I, Lloyd D, et al. (2011) Thioredoxin Reductase-2 Is Essential for Keeping Low Levels of H2O2 Emission from Isolated Heart Mitochondria. Journal of Biological Chemistry 286: 33669-33677.
8. Benhar M, Forrester MT, Hess DT, Stamler JS, (2008) Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 320: 1050-1054.
9. Singer EM, Crocitto LE, Weiss LM, Loera S, Imam SA, et al. (2011) Biomarker Identification with Ligand-Targeted Nucleoprotein Assemblies Nanomedicine (London). 6: 659-668.
10. Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, Becker K, (1998) Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273: 20096-20101.
11. Drechsel DA, Patel M, (2010) Respiration-dependent H2O2 removal in brain mitochondria via the thioredoxin/peroxiredoxin system. J Biol Chem 285: 27850-27858.
12. Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, et al. (1997) Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem 272: 30615-30618.
13. Ayala GE, Muezzinoglu B, Hammerich KH, Frolov A, Liu H, et al. (2011) Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol 178: 79-87.
14. Ayala G, Tuxhorn, J A, Wheeler, T M, et al. (2003) Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 9: 2003.
15. Smith SS, Niu L, Baker DJ, Wendel JA, Kane SE, et al. (1997) Nucleoprotein-based nanoscale assembly. Proc Natl Acad Sci U S A 94: 2162-2167.
16. Wendel JA aSS, (1998) Uracil as an alternative to 5-fluorocytosine in addressable protein targeting. Nanotechnology 9: 297-304.
17. Singer EM, Smith SS, (2006) Nucleoprotein assemblies for cellular biomarker detection. Nano Lett 6: 1184-1189.
18. Clark J, Shevchuk T, Swiderski PM, Dabur R, Crocitto LE, et al. (2003) Mobility-shift analysis with microfluidics chips. Biotechniques 35: 548-554.
19. Huber D, Boyd D, Xia Y, Olma MH, Gerstein M, et al. (2005) Use of thioredoxin as a reporter to identify a subset of Escherichia coli signal sequences that promote signal recognition particle-dependent translocation. J Bacteriol 187: 2983-2991.